肺癌合并肺结核的蛋白组学图谱及差异表达蛋白功能分析

doi:10.3969/j.issn.1006-5725.2024.13.009

Abstract

Abstract:

Objective This study aims to analyze the proteomic characteristics of peripheral blood in patients with lung cancer coexistent with pulmonary tuberculosis （LC?PTB）， identify the differential proteins compared with lung cancer （LC） patients， and conduct functional analysis on these proteins. Methods The study included 8 LC?PTB patients and 10 LC patients. The LC patients were newly diagnosed and confirmed by pathology and did not receive any anti?tumor treatment before， while the PTB patients were Mycobacterium tuberculosis positive at the time of sampling. Liquid chromatography?tandem mass spectrometry （LC?MS/MS） was applied to perform proteomic mass spectrometry to assess the differential proteins， and then functional analysis was conducted via bioinformatics. Results A total of 5，185 proteins were detected between two groups. Through differential expression screening， 190 proteins （58 upregulated and 132 downregulated） were identified to be differentially expressed. Subcellular localization analysis revealed that the differential proteins were mainly concentrated in the cytoplasm， nucleus， and extracellular matrix. KEGG pathway and GO analysis showed the roles of differential proteins in biological processes including immune response， metabolism， and secretion regulation. Protein interaction network analysis highlighted the importance of SORT1， SAR1B， RPS6KB1， VWF， SHC1， SRPRB， CTSD， TARDBP， RPLP0， PSMA2， RPS6， XPO1， PRKACB， and HLA?DRB1 in LC?PTB. Additionally， the expression changes in proteins like ADA2， MAP3K1， and GLS2 might be closely associated with the development of LC?PTB. Conclusions The proteomic profile comprehensively described the proteomic characteristics of LC?PTB and identified numerous differentially expressed proteins， which could provide further clues for research on biological mechanism of LC?PTB.

Key words: lung cancer, pulmonary tuberculosis, proteomics, liquid chromatography?tandem mass spectrometry

CLC Number:

R521.9

Wendi ZHOU,Jiamin LIN,Daichen JU,Qi WANG,Jialou ZHU,Ning SU,Jinxing. HU. Proteomic profiling and functional analysis of differentially expressed proteins in lung cancer coexistent with pulmonary tuberculosis[J]. The Journal of Practical Medicine, 2024, 40(13): 1814-1821.

Figures/Tables 6

Fig. 1

Tab.1

Fig.2

Tab.2

Fig3

Fig.4

References 27

1	SUNG H， FERLAY J， SIEGEL R L， et al. Global Cancer Statistics 2020： GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries［J］. CA Cancer J Clin， 2021， 71（3）： 209-249. doi:10.3322/caac.21660 doi: 10.3322/caac.21660
2	WANG C， WANG Z， WANG G， et al. COVID-19 in early 2021： current status and looking forward［J］. Signal Transduct Target Ther， 2021， 6（1）： 114. doi:10.1038/s41392-021-00527-1 doi: 10.1038/s41392-021-00527-1
3	BAGCCHI S. WHO′s Global Tuberculosis Report 2022［J］. Lancet Microbe， 2023， 4（1）： e20. doi:10.1016/s2666-5247(22)00359-7 doi: 10.1016/s2666-5247(22)00359-7
4	吴惠忠，胡锦兴. 结核病传播研究进展［J］. 实用医学杂志， 2023， 39（19）： 2424-2427. doi:10.3969/j.issn.1006-5725.2023.19.002 doi: 10.3969/j.issn.1006-5725.2023.19.002
5	HWANG S Y， KIM J Y， LEE H S， et al. Pulmonary Tuberculosis and Risk of Lung Cancer： A Systematic Review and Meta-Analysis［J］. J Clin Med，2022， 11（3）：765. doi:10.3390/jcm11030765 doi: 10.3390/jcm11030765
6	ELHADI M， KHALED A， MSHERGHI A. Infectious diseases as a cause of death among cancer patients： a trend analysis and population-based study of outcome in the United States based on the Surveillance， Epidemiology， and End Results database［J］. Infect Agent Cancer， 2021， 16（1）： 72. doi:10.1186/s13027-021-00413-z doi: 10.1186/s13027-021-00413-z
7	XIONG K， SUN W， HE Y， et al. Advances in molecular mechanisms of interaction between Mycobacterium tuberculosis and lung cancer： a narrative review.［J］. Transl Lung Cancer Res，2021， 10（10）： 4012-4026. doi:10.21037/tlcr-21-465 doi: 10.21037/tlcr-21-465
8	中华人民共和国国家卫生和计划生育委员会. 结核病分类（ws196—2017）［J］. 新发传染病电子杂志， 2018（3）：191-192. doi:10.3877/j.issn.2096-2738.2018.03.019 doi: 10.3877/j.issn.2096-2738.2018.03.019
9	YANG L， ZHUANG L， YE Z， et al. Immunotherapy and biomarkers in patients with lung cancer with tuberculosis： Recent advances and future Directions［J］. iScience， 2023， 26（10）： 107881. doi:10.1016/j.isci.2023.107881 doi: 10.1016/j.isci.2023.107881
10	崔兰兰，张革，徐邦牢. 牙龈卟啉单胞菌感染性食管鳞癌细胞外泌体蛋白组学分析［J］. 实用医学杂志， 2023， 39（17）： 2171-2175. doi:10.3969/j.issn.1006-5725.2023.17.004 doi: 10.3969/j.issn.1006-5725.2023.17.004
11	LIU Q， ZHANG J， GUO C， et al. Proteogenomic characterization of small cell lung cancer identifies biological insights and subtype-specific therapeutic strategies［J］. Cell， 2024， 187（1）： 184-203.e28. doi:10.1016/j.cell.2023.12.004 doi: 10.1016/j.cell.2023.12.004
12	GILLETTE M A， SATPATHY S， CAO S， et al. Proteogenomic Characterization Reveals Therapeutic Vulnerabilities in Lung Adenocarcinoma［J］. Cell， 2020， 182（1）： 200-225.e35.
13	ZHANG M， XIE Y， LI S， et al. Proteomics Analysis of Exosomes From Patients With Active Tuberculosis Reveals Infection Profiles and Potential Biomarkers［J］. Front Microbiol， 2022， 12： 800807. doi:10.3389/fmicb.2021.800807 doi: 10.3389/fmicb.2021.800807
14	KALJAS Y， LIU C， SKALDIN M， et al. Human adenosine deaminases ADA1 and ADA2 bind to different subsets of immune cells［J］. Cell Mol Life Sci， 2017， 74（3）： 555-570. doi:10.1007/s00018-016-2357-0 doi: 10.1007/s00018-016-2357-0
15	DELEMARRE E M， VAN HOORN L， BOSSINK A W J， et al. Serum biomarker profile including CCL1， CXCL10， VEGF， and adenosine deaminase activity distinguishes active from remotely acquired latent tuberculosis［J］. Front Immunol， 2021， 12： 725447. doi:10.3389/fimmu.2021.725447 doi: 10.3389/fimmu.2021.725447
16	NAGY Á， LÁNCZKY A， MENYHÁRT O， et al. Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets［J］. Sci Rep， 2018， 8（1）： 9227. doi:10.1038/s41598-018-27521-y doi: 10.1038/s41598-018-27521-y
17	WANG L， LONDONO L M， COWELL J， et al. Targeting adenosine with adenosine deaminase 2 to inhibit growth of solid tumors［J］. Cancer Res， 2021， 81（12）： 3319-3332. doi:10.1158/0008-5472.can-21-0340 doi: 10.1158/0008-5472.can-21-0340
18	LI H， CAO W， CHEN S， et al. Comparative interleukins and chemokines analysis of mice mesenchymal stromal cells infected with mycobacterium tuberculosis H37Rv and H37Ra［J］. Arch Biochem Biophys， 2023， 744： 109673. doi:10.1016/j.abb.2023.109673 doi: 10.1016/j.abb.2023.109673
19	XUE Z， VIS D J， BRUNA A， et al. MAP3K1 and MAP2K4 mutations are associated with sensitivity to MEK inhibitors in multiple cancer models［J］. Cell Res， 2018， 28（7）： 719-729. doi:10.1038/s41422-018-0044-4 doi: 10.1038/s41422-018-0044-4
20	LIU C， WANG S， ZHU S， et al. MAP3K1-targeting therapeutic artificial miRNA suppresses the growth and invasion of breast cancer in vivo and in vitro［J］. Springerplus， 2016， 5： 11. doi:10.1186/s40064-015-1597-z doi: 10.1186/s40064-015-1597-z
21	JIN J， J-K BYUN， Y-K CHOI， et al. Targeting glutamine metabolism as a therapeutic strategy for cancer［J］. Exp Mol Med， 2023， 55（4）： 706-715. doi:10.1038/s12276-023-00971-9 doi: 10.1038/s12276-023-00971-9
22	KOEKEN V A C M， LACHMANDAS E， RIZA A， et al. Role of glutamine metabolism in host defense against mycobacterium tuberculosis infection［J］. J Infect Dis， 2019， 219（10）： 1662-1670. doi:10.1093/infdis/jiy709 doi: 10.1093/infdis/jiy709
23	VÁZQUEZ C L， RODGERS A， HERBST S， et al. The proneurotrophin receptor sortilin is required for Mycobacterium tuberculosis control by macrophages［J］. Sci Rep， 2016， 6： 29332. doi:10.1038/srep29332 doi: 10.1038/srep29332
24	AL-AKHRASS H， NAVES T， VINCENT F， et al. Sortilin limits EGFR signaling by promoting its internalization in lung cancer［J］. Nat Commun， 2017， 8（1）： 1182. doi:10.1038/s41467-017-01172-5 doi: 10.1038/s41467-017-01172-5
25	SCHAAFSMA E， FUGLE C M， WANG X， et al. Pan-cancer association of HLA gene expression with cancer prognosis and immunotherapy efficacy［J］. Br J Cancer， 2021， 125（3）： 422-432. doi:10.1038/s41416-021-01400-2 doi: 10.1038/s41416-021-01400-2
26	SENOSAIN M F， ZOU Y， NOVITSKAYA T， et al. HLA-DR cancer cells expression correlates with T cell infiltration and is enriched in lung adenocarcinoma with indolent behavior［J］. Sci Rep， 2021， 11（1）： 14424. doi:10.1038/s41598-021-93807-3 doi: 10.1038/s41598-021-93807-3
27	YANG P L， HE X J， ZANG Q J， et al. Association of human leukocyte antigen DRB1 polymorphism and tuberculosis： a meta-analysis［J］. Int J Tuberc Lung Dis， 2016， 20（1）： 121-128. doi:10.5588/ijtld.14.0930 doi: 10.5588/ijtld.14.0930

蛋白ID	基因名称	调节方式	变化倍数（LC-PTB/LC）	P值	蛋白功能描述
C9JCN9	HSBP1L1	上调	12.84	0.035 7	转录因子
Q9BW71	HIRIP3	上调	11.97	0.049 4	染色质结构的维护
P10645	CHGA	上调	7.57	0.044 0	参与神经内分泌活动
Q9NZK5	ADA2	上调	6.28	0.047 9	参与调节免疫和炎症反应
Q8NFY9	KBTBD8	上调	6.40	0.012 7	影响细胞功能
Q9UI32	GLS2	下调	-3.51	0.014 5	维护氨基酸和能量代谢，调节神经递质
O14653	GOSR2	下调	-2.89	0.034 5	确保细胞内物质运输以维持稳态
Q13233	MAP3K1	下调	-2.71	0.002 8	细胞信号传导的关键调节因子
Q9UIC8	LCMT1	下调	-2.44	0.001 0	蛋白质后翻译修饰
C9JCN9	SRRM2	下调	-2.06	0.025 6	调控基因表达、维护细胞功能

蛋白ID	基因名称	调节方式	变化倍数（LC-PTB/LC）	P值	蛋白功能描述
Q9H0J4	QRICH2	上调	1.94	0.000 29	调节基因表达和细胞信号传导
Q16363	LAMA4	上调	1.54	0.002 44	影响细胞分化、迁移和信号传导
Q9UJC5	SH3BGRL2	上调	1.74	0.003 62	参与细胞信号传导
P55773	CCL23	上调	1.94	0.004 94	参与免疫调节及炎症反应
Q9BRA2	TXNDC17	上调	1.73	0.006 21	参与氧化还原反应和细胞信号传递
P15291	B4GALT1	下调	-0.78	0.000 02	半乳糖转移酶
P61018	RAB4B	下调	-0.66	0.000 44	细胞内囊泡运输
O00154	ACOT7	下调	-0.88	0.000 87	参与脂肪酸代谢
Q9UIC8	LCMT1	下调	-2.44	0.001 02	翻译后甲基化修饰
P23443	RPS6KB1	下调	-0.65	0.001 09	调节蛋白质合成

[1]	Qi CHEN,Yaxi ZHANG,Mingxia ZHANG,Jieyun ZHANG,Qianting. YANG. The detection value of tuberculosis-specific QFT-TB in different types of specimens of tuberculosis patients [J]. The Journal of Practical Medicine, 2024, 40(7): 1002-1005.
[2]	Zishen LIU,Yingying ZHENG,Mengqi YUAN,Ganlin ZHANG,Guowang. YANG. The causal relationship between chemokine CCL2 and lung cancer： a two⁃sample Mendelian randomization study [J]. The Journal of Practical Medicine, 2024, 40(4): 532-536.
[3]	Jiaming YANG,Shi XIE,Haishen ZHOU,Jiaqing ZHANG. A comparative study of clinical features and lymph node metastasis risk between early multi⁃primary and singlee pulmonary adenocarcinoma nodules [J]. The Journal of Practical Medicine, 2024, 40(22): 3208-3214.
[4]	Linlin GAI,Weice SUN,Jinjin CHU,Donghua XU. Changes of M1/M2 macrophages polarization associated with active pulmonary tuberculosis and the effect of ESAT6 on macrophage polarization [J]. The Journal of Practical Medicine, 2024, 40(20): 2867-2873.
[5]	Xinpan LI,Yi FANG,Jun QIU. Predictive value of CD3⁺/CD4⁺T lymphocyte level and neutrophil to lymphocyte ratio in radiation pneumonia [J]. The Journal of Practical Medicine, 2024, 40(20): 2923-2928.
[6]	Haojie TANG,Zilong YANG,Zhaoxian YU,Zhiyu FENG,Haiping DONG,Xiang LI,Wei ZHAO,Haobin. KUANG. Construction and evaluation of a risk prediction model for linezolid-related neurological adverse reactions in patients with multidrug-resistant tuberculosis [J]. The Journal of Practical Medicine, 2024, 40(19): 2690-2695.
[7]	Ling ZHU,Dewang REN,Runyang MA,Guowei LIANG,Xuejun. DOU. Methylation levels of the HIST1H4F gene mRNA region DNA and its diagnostic value in lung cancer tissues [J]. The Journal of Practical Medicine, 2024, 40(19): 2726-2732.
[8]	Xueyan HU,Fanliang MENG,Juanjuan. DONG. Prognostic analysis of patients with bone metastases from primary non-small cell lung cancer with different pathologic staging [J]. The Journal of Practical Medicine, 2024, 40(16): 2316-2325.
[9]	Shengfang YUAN,Bu WANG,Baoli XIANG,Jianqing ZHAO,Jingjing SHEN,Zhihua. ZHANG. Prediction of immune therapy efficacy and prognosis for advanced non-small cell lung cancer using peripheral blood circulation tumor DNA [J]. The Journal of Practical Medicine, 2024, 40(15): 2110-2115.
[10]	Lanrong WANG,Xiaocui WANG,Yang CAO,Rui LI,Weihong WANG,Yingxi XU,Weixiang SHI,Yufei YANG,Ke MENG,Wei. ZHANG. A cross⁃sectional study on the risk of early screening for lung cancer in Zhengzhou City [J]. The Journal of Practical Medicine, 2024, 40(15): 2154-2160.
[11]	Yuting LI,Qilu YAN,Qibin. SONG. Molecular basis of variability in EGFR⁃targeted therapy response in non⁃small cell lung cancer [J]. The Journal of Practical Medicine, 2024, 40(15): 2166-2171.
[12]	Jing GUI,Feng WANG,Hui YANG,Yumao CAI,Chuangyue. HONG. Investigation of oxidised low⁃density lipoprotein as a risk assessment indicator in patients with type 2 diabetes mellitus combined with pulmonary tuberculosis [J]. The Journal of Practical Medicine, 2024, 40(14): 1995-2002.
[13]	Sijie ZHENG,Jia XIANG,Qiantong CHEN,Yingxin LU,Yun LIU,Huai CHEN,Suidan. HUANG. Differential diagnostic value of wide⁃body spectral CT parameters in mediastinal metastatic， non⁃metastatic lymph nodes of lung cancer patients and reactive hyperplastic lymph nodes [J]. The Journal of Practical Medicine, 2024, 40(14): 2003-2008.
[14]	Xue MA,Shihui. ZHOU. Role and potential mechanisms of p62/SQSTM1 on migration and metastasis of non⁃small cell lung cancer [J]. The Journal of Practical Medicine, 2024, 40(1): 13-18.
[15]	Yang WU,Jian YAO,Jinliang. CHEN. The mechanism of lipid metabolism disorders promoting progression of lung cancer based on the oxLDL/LOX⁃1 signaling pathway [J]. The Journal of Practical Medicine, 2024, 40(1): 19-24.

Proteomic profiling and functional analysis of differentially expressed proteins in lung cancer coexistent with pulmonary tuberculosis

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 6

References 27

Related Articles 15

Recommended Articles

Metrics

Comments